Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CMV gB/MF59 Vaccine in Adolescent Females
NCT00133497Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2006
- Primary completion
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cytomegalovirus subunit vaccine glycoprotein B in cytomegalovirus infection (CMV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2006; status: completed.
02
Drugs
cytomegalovirus subunit vaccine glycoprotein B
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00133497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133497.